Filing Flows › Insmed (INSM) › Q3 2026
Insmed (INSM) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Insmed (INSM) reported revenue of $524M for the third quarter 2026 (Q3 2026), +268% from a year earlier and +23% from the quarter before. Operating margin was -17.0%, net loss $100M (19.1% of revenue).
Insmed, Q3 2026: revenue $524M (+268% year over year), operating margin -17.0%, net loss $100M, operating cash flow −$36.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $524M | +23% | +268% |
| Operating profit | −$89.4M | — | — |
| Net earnings | −$100M | — | — |
| Operating cash flow | −$36.5M | — | — |
What changed
Revenue was $524.4M in Q3 2026, up 268% year over year and up 23% from the previous quarter. BRINSUPRI was the largest line at 76% of revenue. BRINSUPRI added $372.0M year over year (up 1326%), 97% of the total change.
Operating costs exceeded revenue by $89.4M, an operating margin of -17.0%. Total costs grew 21% against revenue growth of 268%. The fastest-growing cost line was Cost of revenue (+166%). The quarter ended with a net loss of $100.3M, wider than the previous quarter's $13.2M loss.
Operating cash flow was −$36.5M. Non-cash charges added back $8.4M of depreciation and amortization and $41.2M of share-based compensation. Working capital and other items added $14.2M. Capital expenditures of $5.6M exceeded it, leaving free cash flow of −$42.1M.
Questions
What was Insmed's revenue in the third quarter 2026?
Insmed (INSM) reported revenue of $524M for the third quarter 2026 (Q3 2026), +268% from a year earlier and +23% from the quarter before.
Was Insmed profitable in the third quarter 2026?
Operating loss was $89.4M (-17.0% of revenue) and net loss $100M.
Source: Insmed 10-Q on SEC EDGAR.